KPC(SH:600422) Xin Jing Bao·2026-01-06 08:08Core Viewpoint - Kunming Pharmaceutical Group has undergone a significant leadership change, with a complete overhaul of its core decision-making and operational teams, aiming to address recent performance challenges and adapt to external market pressures [1][2][3][4] Leadership Changes - Yu Xiang has been appointed as the new chairman, with a term lasting until January 22, 2028, succeeding Wu Wendo, who will remain on the board [1] - The new president, Zhong Jiang, has been appointed alongside Yu Xiang, with both leaders coming from the China Resources system, indicating a strategic shift in management [2][3] - Former president Yan Wei will transition to the role of vice chairman and board member, while former vice president Li Lichun will no longer hold any positions within the company [2] Financial Performance - Kunming Pharmaceutical Group has faced significant financial pressure, with a reported revenue of 4.751 billion yuan for the first three quarters of 2025, marking an 18.08% year-on-year decline [3] - The net profit attributable to shareholders decreased by 39.42% to 269 million yuan, while the net profit after deducting non-recurring items fell by 59.52% [3] - The company's accounts receivable have increased dramatically, rising from 1.358 billion yuan in mid-2020 to 3.25 billion yuan in mid-2025, a cumulative increase of 139.32% [3] Business Challenges - The primary revenue source, the Xuesaitong series, which accounts for approximately 40% of total revenue, is under pressure from price suppression due to centralized procurement policies, despite showing signs of recovery [4] - The premium traditional Chinese medicine segment, making up about 30% of revenue, is currently undergoing brand upgrades and channel restructuring, lacking stable growth momentum [4] - The new leadership team is expected to integrate resources and implement strategies to gradually restore the company's performance amidst these challenges [4]